Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
TIBOLON, LIVILAN, TIBOLONE GENPAR, TIBOLONE GPPL, APO-TIBOLONE, TERRY WHITE CHEMISTS TIBOLONE, CHEMMART TIBOLONE (Generic Partners Pty Ltd)
Product name
TIBOLON, LIVILAN, TIBOLONE GENPAR, TIBOLONE GPPL, APO-TIBOLONE, TERRY WHITE CHEMISTS TIBOLONE, CHEMMART TIBOLONE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
253 working days (255)
Active ingredients
tibolone
Registration type
New generic medicine
Indication
Tibolone (tablets) is indicated for:
- Short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women.
- Second line of therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss.